| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
7,399 |
5,844 |
$208K |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
3,941 |
3,328 |
$158K |
| 95165 |
Professional services for the supervision of preparation and provision of antigens for allergen immunotherapy, multiple dose vials |
442 |
417 |
$110K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
2,053 |
1,596 |
$68K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
3,193 |
2,677 |
$56K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
1,578 |
1,437 |
$53K |
| 86328 |
|
1,400 |
1,098 |
$53K |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
5,248 |
4,250 |
$52K |
| 99202 |
Office or other outpatient visit for the evaluation and management of a new patient, straightforward |
579 |
516 |
$16K |
| 99396 |
Periodic comprehensive preventive medicine reevaluation, established patient, 40-64 years |
109 |
102 |
$7K |
| 93000 |
|
762 |
699 |
$7K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
235 |
194 |
$6K |
| U0003 |
Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r |
130 |
110 |
$6K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
135 |
76 |
$5K |
| 99395 |
Periodic comprehensive preventive medicine reevaluation, established patient, 18-39 years |
73 |
68 |
$4K |
| 99091 |
|
211 |
204 |
$3K |
| 99385 |
|
52 |
48 |
$3K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
286 |
247 |
$3K |
| 0001A |
|
76 |
67 |
$2K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
303 |
190 |
$2K |
| 0002A |
|
68 |
62 |
$2K |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
238 |
191 |
$2K |
| 87635 |
Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe |
39 |
37 |
$2K |
| 99211 |
Office or other outpatient visit for the evaluation and management of an established patient, minimal severity |
136 |
108 |
$2K |
| 96130 |
|
1,070 |
927 |
$2K |
| 90688 |
|
163 |
133 |
$1K |
| 99000 |
|
160 |
143 |
$1K |
| 99386 |
|
14 |
13 |
$897.31 |
| 99204 |
Office or other outpatient visit for the evaluation and management of a new patient, moderate complexity |
13 |
12 |
$870.83 |
| 99457 |
|
299 |
286 |
$477.06 |
| 86769 |
|
15 |
13 |
$476.46 |
| 99490 |
Ccm add 20min |
292 |
254 |
$278.66 |
| 99458 |
|
220 |
210 |
$265.53 |
| 96373 |
|
16 |
15 |
$225.56 |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
16 |
15 |
$215.85 |
| G0444 |
Annual depression screening, 5 to 15 minutes |
1,580 |
1,369 |
$177.55 |
| G0442 |
Annual alcohol misuse screening, 5 to 15 minutes |
1,543 |
1,336 |
$177.55 |
| 99439 |
|
266 |
230 |
$127.30 |
| 81003 |
|
95 |
82 |
$80.71 |
| 99401 |
|
2,384 |
1,959 |
$57.00 |
| 99454 |
|
105 |
97 |
$55.28 |
| 36415 |
Collection of venous blood by venipuncture |
482 |
398 |
$23.46 |
| 99072 |
|
534 |
446 |
$9.98 |
| 97803 |
|
106 |
92 |
$0.00 |
| 96127 |
|
157 |
143 |
$0.00 |
| G0108 |
Diabetes outpatient self-management training services, individual, per 30 minutes |
436 |
383 |
$0.00 |
| 97802 |
|
76 |
61 |
$0.00 |
| 96161 |
|
16 |
14 |
$0.00 |